ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 332,93
-0,31%
Dow Jones
42 992,21
-0,77%
DAX
19 929,23
-0,15%
Brent Oil
73,47
-0,21%
Bitcoin
93 574,06
0,06%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Amgen Inc (AMGN)

  7. Amgen Inc (AMGN) Actualités

AMGN

Amgen (AMGN)

Amgen Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AMGN
DateHeureSourceTitreSymboleSociété
10/12/202422h30PR Newswire (US)AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDENDNASDAQ:AMGNAmgen Inc
07/12/202416h00PR Newswire (US)BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)NASDAQ:AMGNAmgen Inc
07/12/202400h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMGNAmgen Inc
05/12/202415h00PR Newswire (US)AMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINANASDAQ:AMGNAmgen Inc
02/12/202422h00PR Newswire (US)AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
29/11/202422h30PR Newswire (US)AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCENASDAQ:AMGNAmgen Inc
26/11/202413h05PR Newswire (US)AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDYNASDAQ:AMGNAmgen Inc
26/11/202413h00PR Newswire (US)AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAMNASDAQ:AMGNAmgen Inc
20/11/202422h00PR Newswire (US)AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENTNASDAQ:AMGNAmgen Inc
14/11/202422h00PR Newswire (US)AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024NASDAQ:AMGNAmgen Inc
13/11/202421h27PR Newswire (US)MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRMNASDAQ:AMGNAmgen Inc
13/11/202411h00PR Newswire (US)AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATANASDAQ:AMGNAmgen Inc
08/11/202422h00PR Newswire (US)AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
08/11/202408h00PR Newswire (US)TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPSNASDAQ:AMGNAmgen Inc
31/10/202412h13IH Market NewsMicrosoft and Meta Decline Up to 4%; Roku Falls 14% Amid Lower Estimates; Booking Surges 6%; Carvana Soars 20%NASDAQ:AMGNAmgen Inc
30/10/202421h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMGNAmgen Inc
30/10/202421h01PR Newswire (US)AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTSNASDAQ:AMGNAmgen Inc
25/10/202422h00PR Newswire (US)AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDENDNASDAQ:AMGNAmgen Inc
24/10/202422h00PR Newswire (US)AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTSNASDAQ:AMGNAmgen Inc
15/10/202414h00PR Newswire (US)AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024NASDAQ:AMGNAmgen Inc
01/10/202415h00PR Newswire (US)LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFENASDAQ:AMGNAmgen Inc
25/09/202422h45IH Market NewsDow, S&P Come Off Record Highs, Close On Weak NoteNASDAQ:AMGNAmgen Inc
24/09/202422h00PR Newswire (US)TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASENASDAQ:AMGNAmgen Inc
23/09/202422h00PR Newswire (US)AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASENASDAQ:AMGNAmgen Inc
13/09/202415h00PR Newswire (US)AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024NASDAQ:AMGNAmgen Inc
09/09/202415h00PR Newswire (US)AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024NASDAQ:AMGNAmgen Inc
30/08/202422h00PR Newswire (US)AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
29/08/202422h00PR Newswire (US)AMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCENASDAQ:AMGNAmgen Inc
23/08/202422h20Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AMGNAmgen Inc
20/08/202415h00PR Newswire (US)OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASISNASDAQ:AMGNAmgen Inc
 Showing the most relevant articles for your search:NASDAQ:AMGN

Dernières Valeurs Consultées

TG
D4G
DataMetrex AI
AMEX
IAU
iShares Gold
COIN
BLCTUSD
Bloomzed Loyalty Club Ticket
BITMOT
2886200
Ifc Zc Nov47 Mxn
EU
IWEL3
AMUNDI WEL3 INAV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés